Company Encyclopedia
View More
name
Keros Therapeutics
KROS.US
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd.
1.946 T
KROS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking37/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.43%B
    • Profit Margin26.12%A
    • Gross Margin-36.86%E
  • Growth ScoreA
    • Revenue YoY37798.31%A
    • Net Profit YoY135.50%A
    • Total Assets YoY28.23%A
    • Net Assets YoY32.04%A
  • Cash ScoreB
    • Cash Flow Margin382.81%C
    • OCF YoY37798.31%A
  • Operating ScoreC
    • Turnover0.37C
  • Debt ScoreA
    • Gearing Ratio5.28%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Keros Therapeutics Announces Final Results Of Tender Offer

    Keros Therapeutics Inc:* KEROS THERAPEUTICS ANNOUNCES FINAL RESULTS OF TENDER OFFER Source text: Further company coverage:

    Reuters·
    US
    KROS
    +11.99%
    Reuters·
    US
    KROS
    +11.99%

    Keros Therapeutics Announces Preliminary Results of Tender Offer

    LEXINGTON, Mass., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Keros Therapeutics, Inc. ( "Keros" or the "Company" ) ( Nasdaq: KROS ) , today announced the preliminary results of its cash tender offer ( the "Tender Offer" ) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase ...

    GlobeNewswire·
    US
    KROS
    +11.99%
    GlobeNewswire·
    US
    KROS
    +11.99%

    Keros Therapeutics (KROS) Gets a Buy from Oppenheimer

    Oppenheimer analyst Andreas Argyrides has maintained a Buy rating on Keros Therapeutics (KROS) with a price target of $27.00. Argyrides, who focuses on the Healthcare sector, has an average return of 13.1% and a 46.59% success rate on his recommendations. Additionally, Wells Fargo's Benjamin Burnett also issued a Buy rating for Keros, while Wedbush maintained a Hold rating on November 6.

    Tip Ranks·
    US
    KROS
    +11.99%
    Tip Ranks·
    US
    KROS
    +11.99%

    Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships

    Andres Y. Maldonado from H.C. Wainwright has reiterated a Buy rating for Keros Therapeutics, maintaining a price target of $20.00. The positive outlook is driven by the company's focus on KER 065, which has shown promising Phase 1 trial results for Duchenne Muscular Dystrophy. Additionally, a partnership with Takeda enhances financial stability through potential milestones and royalties. The strategic direction and improved balance sheet further support the investment case, aiming to drive long-term shareholder value.

    Tip Ranks·
    US
    KROS
    +11.99%
    Tip Ranks·
    US
    KROS
    +11.99%

    Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties

    Keros Therapeutics has received a Hold rating from Matt Phipps due to its strategic focus on KER-065 and financial uncertainties. The company plans to start a Phase II trial for Duchenne muscular dystrophy in early 2026, which poses risks if not successful. Additionally, a $375 million capital return may affect financial flexibility. While potential milestones from a license agreement with Takeda could offer future benefits, they depend on successful development. Phipps suggests a Hold rating as Keros navigates these challenges.

    Tip Ranks·
    US
    KROS
    +11.99%
    Tip Ranks·
    US
    KROS
    +11.99%
    © 2025 Longbridge｜Disclaimer